|
|
|
Volumn 2 Suppl 2, Issue , 2004, Pages
|
|
EGFR inhibition in NSCLC: the emerging role of cetuximab.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
MONOCLONAL ANTIBODY;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
QUINAZOLINE DERIVATIVE;
TAXOID;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG COMBINATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
REVIEW;
STATISTICS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS AS TOPIC;
DRUG THERAPY, COMBINATION;
HUMANS;
LUNG NEOPLASMS;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TAXOIDS;
|
|
EID: 73349108495
PISSN: 15401405
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (3)
|
|
References (62)
|
